Tracking Cathie Wood: Continued Accumulation of CRSP! Focused on the 2026 Healthcare Theme
On Friday (December 26), U.S. equities traded in a narrow range, with the three major indices collectively posting slight declines, ending a five-day winning streak.
ARK Invest continues to focus on gene editing — solely purchasing $CRISPR Therapeutics (CRSP.US)$ over 20,000 shares. ARK Invest's continued accumulation of CRSP reflects its confidence in the company’s core technological edge in the CRISPR field. This stock not only aligns perfectly with Wall Street's 2026 "Healthcare Innovation" investment theme but also exhibits both "counter-cyclical" and "high-growth" attributes.
![On Friday (December 26), U.S. equities traded in a narrow range, with the three major indices collectively posting slight declines, ending a five-day winning streak. ARK Invest continues to focus on gene editing — solely purchasing $CRISPR Therapeutics (CRSP.US)$ over 20,000 shares. ARK Invest's continued accumulation of CRSP reflects its confidence in the company’s core technological edge in the CRISPR field. This stock not only aligns perfectly with Wall Street's 2026 "Healthcare Innovation" investment theme but also exhibits both "counter-cyclical" and "high-growth" attributes. [Cool Guy]Futubull's [Opportunities Page] has launched tracking for celebrity portfolio opportunities! Choose from multiple celebrity portfolios, follow the masters' strategies with one click, precisely lock onto high-quality targets, and invest with greater confidence!](https://nnqimage.futunn.com/sns_client_feed/948888/20251229/web-1766990114046-qK1F3HvHaW.png/big?area=1&is_public=true&imageMogr2/ignore-error/1/format/webp)
Futubull's [Opportunities Page] has launched tracking for celebrity portfolio opportunities! Choose from multiple celebrity portfolios, follow the masters' strategies with one click, precisely lock onto high-quality targets, and invest with greater confidence!![On Friday (December 26), U.S. equities traded in a narrow range, with the three major indices collectively posting slight declines, ending a five-day winning streak. ARK Invest continues to focus on gene editing — solely purchasing $CRISPR Therapeutics (CRSP.US)$ over 20,000 shares. ARK Invest's continued accumulation of CRSP reflects its confidence in the company’s core technological edge in the CRISPR field. This stock not only aligns perfectly with Wall Street's 2026 "Healthcare Innovation" investment theme but also exhibits both "counter-cyclical" and "high-growth" attributes. [Cool Guy]Futubull's [Opportunities Page] has launched tracking for celebrity portfolio opportunities! Choose from multiple celebrity portfolios, follow the masters' strategies with one click, precisely lock onto high-quality targets, and invest with greater confidence!](https://nnqimage.futunn.com/sns_client_feed/948888/20251229/web-1766990114259-a06aU96WzJ.png/big?area=1&is_public=true&imageMogr2/ignore-error/1/format/webp)
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Comments
to post a comment
7
5